To engage with Italian and American stakeholders active in biotech and life sciences, on November 14th at the Farnesina Palace in Rome, the “Italy – USA: International Cooperation on Emerging Biotechnologies and Life Sciences” event will be held, with Edra as the media partner.

Scientific sectors such as biotechnology are characterized by a high intensity of knowledge and research and development, rapid cycles of innovation, and highly qualified personnel, with a higher percentage of employed women compared to the national average. It is estimated that each employee in high-tech sectors generates another 5 in related fields.

To engage with Italian and American stakeholders active in biotech and life sciences, on November 14th at the Farnesina Palace in Rome, the “Italy – USA: International Cooperation on Emerging Biotechnologies and Life Sciences” event will be held, with Edra as media partner.

This is the first high-level institutional and entrepreneurial meeting between Italian and American stakeholders active in the biotechnology and life sciences sector. The conference aims to initiate a long-term bilateral dialogue on emerging biotechnologies and life sciences, specifically examining international strategies for cooperation, funding opportunities, and research and development models.

As demonstrated by the pandemic, biotechnologies and life sciences are sectors of strategic interest related to national security, making the role of governments crucial in providing leadership and guidance. In this context, it is imperative to develop international strategic partnerships with allies and countries that share similar perspectives.

Italy hosts a vibrant and growing biotechnology and life sciences sector, where public and private actors interact dynamically, with an annual turnover exceeding 250 billion euros. The research and development volume of Italian pharmaceutical, medical device, and biotechnology industries amounts to approximately 3 billion euros per year (11% of the country’s total). In terms of Venture Capital, biotechnology and life sciences are among the most active verticals. Over the past five years, global private equity has invested nearly 400 billion euros; in Europe, private equity and venture capital have committed over 75 billion euros, with more than six billion euros invested in Italy in almost 300 companies. In particular, international funds in our country have invested over 4.5 billion euros in five years, accounting for 76% of the capital allocated to life sciences. If in 2018, 5 targets were financed, by 2022, this number has increased to 17, indicating the importance of this segment for foreign investors.

Click here to download the Agenda.

Overbooked event.